Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Articles

Researchers behind the phase 3 studies gave pearls into the study methods, results, and what is up next.

Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Social media misinformation related to acne vulgaris may require clinician intervention when discussing treatment with patients.

Physicians Should Prepare for Potential Acne Vulgaris Misinformation Correction, Report Says

Margins < 1 mm also do not increase the risk of cutaneous squamous cell carcinoma recurrence risk if the galea aponeurotica is not involved.








Deep Histological Margins Do Not Increase cSCC Recurrence Risk if Tumor is Fully Excised

A recent study saw a “significant” decrease in allergen-specific IgE levels over a 1-year period of dupilumab therapy in children with atopic dermatitis. 

POLL: Have You Ever Treated Blastic Plasmacytoid Dendritic Cell Neoplasm?